Compare FTCI & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTCI | VRCA |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.4M | 137.3M |
| IPO Year | 2021 | 2018 |
| Metric | FTCI | VRCA |
|---|---|---|
| Price | $4.37 | $5.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | $10.80 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 193.1K | 85.5K |
| Earning Date | 05-01-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $99,687,000.00 | $35,577,000.00 |
| Revenue This Year | $65.44 | N/A |
| Revenue Next Year | $45.97 | $94.44 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 110.51 | ★ 370.22 |
| 52 Week Low | $3.21 | $0.49 |
| 52 Week High | $12.75 | $9.82 |
| Indicator | FTCI | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 45.98 | 39.60 |
| Support Level | $3.30 | $5.13 |
| Resistance Level | $5.31 | $6.40 |
| Average True Range (ATR) | 0.54 | 0.68 |
| MACD | 0.01 | -0.22 |
| Stochastic Oscillator | 50.36 | 4.42 |
FTC Solar Inc is a provider of solar tracker systems, supported by proprietary software and value-added engineering services. The company's Solar tracker systems move solar panels throughout the day to maintain an optimal orientation relative to the sun, thereby increasing the amount of solar energy produced at a solar installation. It focuses on providing differentiated products, software, and services that maximize energy generation. The company has launched a new mounting solution to support the installation and use of U.S. manufactured thin-film modules by project owners. The only segment the company is engaged in is the Manufacturing and Servicing of Solar tracker systems.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.